Compounded semaglutide is currently available through licensed telehealth clinics in the United States, but the legal picture in 2026 is more complicated than it was just two years ago. The FDA has moved aggressively to restrict large-scale compounding now that the original drug shortage has been resolved, and a formal regulatory proposal — with a public comment deadline of June 29, 2026 — could finalize those restrictions permanently. This guide explains exactly where things stand right now and what it means for you.
Independent editorial. We do not prescribe or sell medication. Updated June 2026.
The short answer
Yes — compounded semaglutide is currently accessible through licensed telehealth clinics for most patients in the United States. The clinics we review on this site dispense compounded GLP-1 medication prepared by state-licensed pharmacies operating under a valid clinician's prescription.
However, the regulatory landscape is actively shifting. The FDA has formally restricted large-scale outsourcing facilities from compounding semaglutide and tirzepatide, and a new proposal published April 30, 2026 would codify a permanent bar on large-scale outsourcing production. A public comment period runs through June 29, 2026. The final rule could affect how and where compounded semaglutide is prepared — but the patient-specific prescription model used by most telehealth clinics sits on firmer legal footing than bulk outsourcing.
The practical takeaway for patients: if you are currently on compounded semaglutide from a licensed telehealth clinic, you do not need to stop. But you should understand the regulatory context and stay in contact with your provider, because this landscape is still evolving.
What compounded semaglutide is — and why it matters so much right now
Semaglutide is the active ingredient in two FDA-approved brand-name drugs: Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). Compounded semaglutide is a version of the same molecule prepared by a licensed compounding pharmacy rather than by the drug's manufacturer. The FDA reviews brand-name drugs for safety, efficacy, and quality through its standard approval process. Compounded drugs do not go through that same review — which is why the agency's position on the legal justification for compounding them matters so much.
The cost gap is why this debate affects so many people. Brand-name Wegovy lists near $1,000–$1,350 a month without insurance. Compounded semaglutide typically starts at $147–$300 a month from online clinics. For patients paying cash — the large majority in the online weight-loss space — that difference defines whether GLP-1 treatment is financially possible at all.
The growth of compounded semaglutide was legally enabled by a specific statutory mechanism: the drug shortage exemption. When a drug is on the FDA's official shortage list, federal compounding law (Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act) allows licensed pharmacies to prepare and dispense it more broadly than would otherwise be permitted. Semaglutide landed on the shortage list as demand for weight-loss treatment exploded in 2023 and outpaced manufacturer supply for roughly two years.
Why the FDA began cracking down — the shortage rationale ran out
The legal foundation for widespread compounded semaglutide was always conditional on the shortage designation. The moment the FDA declared the shortage resolved, that foundation started to erode.
The FDA announced in early 2025 that the semaglutide shortage was no longer in effect. Tirzepatide (the active ingredient in Mounjaro and Zepbound) had been resolved from shortage even earlier — October 2024. Once a drug comes off the shortage list, the broad compounding exemption no longer automatically applies.
The FDA did not flip a switch immediately. It gave outsourcing facilities (503B pharmacies — larger operations that compound drugs at scale) a wind-down period, initially through May 2025, with extensions following litigation. For smaller 503A pharmacies — those that compound for individual patients under a specific, valid prescription — the FDA exercised enforcement discretion, signaling it would not broadly pursue action in cases where a licensed clinician had written a patient-specific prescription with a documented clinical rationale.
This is the core of why most online GLP-1 telehealth clinics continued operating: they operate, or partner with pharmacies that operate, under the 503A patient-specific model. A patient has a telehealth visit, a licensed clinician evaluates them and writes a prescription for that specific patient, and a licensed 503A compounding pharmacy fills it. That model has always been the backbone of traditional pharmacy compounding law and does not depend on the shortage designation the way large-scale bulk compounding does.
503A versus 503B: the legal distinction that shapes everything
Whether compounded semaglutide is legal for you today depends heavily on which type of compounding pharmacy prepared it.
| 503A (traditional pharmacy) | 503B (outsourcing facility) | |
|---|---|---|
| Licensing | State pharmacy board | FDA-registered federal |
| Patient Rx required | Yes — patient-specific | No — can compound without individual Rx |
| Scale | Small / individual-patient | Large-scale / bulk |
| Shortage required? | No (patient-specific medical need) | Yes (or drug must be on 503B bulks list) |
| Status for sema/tirz | Operational (enforcement discretion) | Restricted since shortage resolved |
503A pharmacies can still compound semaglutide for an individual patient if a licensed prescriber has determined that the commercially available product does not meet that patient's specific medical need and has written a valid prescription. FDA enforcement discretion has generally covered this pathway, even after the shortage resolution, for bona fide patient-specific prescriptions written by a clinician who has evaluated the patient.
503B outsourcing facilities operate at much larger scale. They can compound drugs without patient-specific prescriptions, but only when the drug is on the FDA's shortage list OR on the agency's official 503B bulks list. When semaglutide was removed from the shortage list, 503B facilities lost their primary legal basis for large-scale production of compounded semaglutide.
If you are getting compounded semaglutide from a licensed telehealth clinic today, you are most likely on the 503A track: a clinician evaluated you individually, wrote a prescription, and a 503A pharmacy filled it for you specifically.
Compounded semaglutide: the current legal landscape in 2026
As of June 2026, here is the honest picture:
What is currently operational: Telehealth clinics that use 503A pharmacy partners — dispensing compounded semaglutide and compounded tirzepatide to patients who hold a valid prescription from a licensed clinician — are operating within the current enforcement environment. The FDA's published enforcement priorities have focused on large-scale outsourcing facilities, not on patient-specific 503A dispensing under a clinician's supervision.
What has been restricted: Large-scale 503B outsourcing facilities can no longer legally produce compounded semaglutide or tirzepatide under the shortage rationale. Those that attempted to continue faced FDA enforcement action. Some facilities and compounding pharmacy advocacy groups pursued legal challenges; rulings have been mixed and litigation remains active in some jurisdictions.
What is proposed but not yet final: On April 30, 2026, the FDA published a Notice of Proposed Rulemaking to formally exclude semaglutide and tirzepatide from the list of bulk drug substances that 503B outsourcing facilities are permitted to compound. The public comment period closes June 29, 2026. After comment, the FDA will review submissions and issue a final rule — a process that typically takes months to years.
The 503A patient-specific pathway is not directly targeted by the April 2026 proposal. But the overall regulatory trend is tightening, and any final rule will continue to shape the operating environment for the compounding pharmacies that online GLP-1 clinics rely on.
What the April 2026 FDA proposal actually says
The April 30 notice is a formal rulemaking action proposing to remove semaglutide and tirzepatide from the 503B outsourcing facility compoundable bulks list. In plain terms, the FDA is proposing to make permanent a position it has been enforcing informally since 2025: that brand manufacturers have resolved the shortage, brand supply is adequate to meet demand, and therefore large-scale compounding of these specific drugs is no longer legally justified under the 503B framework.
What the proposal does:
- Initiates the formal federal rulemaking process for the 503B exclusion
- Makes the FDA's position on 503B compounding of semaglutide and tirzepatide a matter of binding regulation rather than enforcement guidance
- Invites public comments from patients, clinicians, pharmacies, and advocacy groups through June 29
What the proposal does not immediately do:
- It does not create new restrictions on 503A patient-specific compounding
- It does not immediately change what is currently available from licensed telehealth clinics
- It is a proposed rule — the FDA must review all comments and publish a final rule before it carries legal force
You can review the proposal and submit a public comment through FDA.gov during the open comment window if you want to weigh in.
Compounded tirzepatide is in the same regulatory position
Everything described above applies equally to compounded tirzepatide, the active ingredient in Mounjaro and Zepbound. Tirzepatide was resolved from shortage before semaglutide (October 2024), and the April 2026 proposal explicitly names tirzepatide alongside semaglutide.
Clinics offering compounded tirzepatide are operating under parallel conditions: 503A patient-specific prescriptions continue under enforcement discretion; 503B large-scale production has faced the same wind-down pressure. If you are deciding between the two medications, the regulatory risk profile is essentially identical. For the clinical differences — effectiveness, side-effect profile, dosing — see our semaglutide vs. tirzepatide comparison.
What to do if you are currently on compounded GLP-1 medication
Do not make any abrupt medication changes on your own. Here is practical guidance organized by situation:
If you are currently taking compounded semaglutide from a telehealth clinic:
-
Keep your prescription active. As long as you have a current prescription from a licensed clinician and your clinic uses a 503A pharmacy, your situation is stable under the current enforcement environment. Do not stop without talking to your provider.
-
Stay in contact with your clinic. Reputable telehealth clinics communicate proactively about regulatory changes. If your clinic shifts its pharmacy partner or its compounding model, you want to hear about it from them — not discover it when your refill doesn't arrive.
-
Understand the cost of alternatives. Brand-name Wegovy (semaglutide, FDA-approved) and Zepbound (tirzepatide, FDA-approved) are the commercially available options if compounded versions become less accessible. Their cash list prices are much higher, but insurance coverage and manufacturer savings programs can narrow the gap in some cases. Our GLP-1 cost guide covers what to budget across all options.
If you are starting to look for a GLP-1 clinic:
-
Stick with licensed, transparent providers. Compounded semaglutide from a licensed clinic operating through a 503A pharmacy with a valid prescription is the legally sound approach. Avoid any source that does not require a clinician consultation and a valid prescription — that is a regulatory red flag and a safety flag.
-
Ask about the pharmacy. A legitimate clinic will be able to tell you what type of compounding pharmacy prepares your medication (503A or 503B) and where it is located. If they can't or won't answer, that is a red flag. Our safety guide covers what questions to ask before committing.
-
Check clinic rankings. We score the clinics we track on clinical oversight, pricing transparency, treatment options, experience, and trust. Among the five we have independently reviewed and approved, Gala Health earns the highest overall score and has the broadest medication menu. View all ranked clinics →
Frequently asked questions
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is prepared by licensed pharmacies but is not FDA-approved. The FDA approves brand-name drugs — Wegovy and Ozempic — through its full safety, efficacy, and quality review. Compounded drugs do not go through that process. This does not automatically make them unsafe, but it does mean independent regulatory verification of their purity, dosing accuracy, and sterility has not been completed by the FDA.
What happened to the shortage that made compounded semaglutide legal in the first place?
When demand for semaglutide exploded in 2023–2024, manufacturer supply could not keep up and the FDA placed it on its official drug shortage list. That shortage designation unlocked broader compounding permissions under federal law. The FDA determined in early 2025 that the shortage was resolved — manufacturer supply had stabilized — which removed the primary legal justification for large-scale outsourcing facility production.
Does the April 2026 FDA proposal affect 503A patient-specific compounding?
The current proposal targets 503B outsourcing facilities specifically. It does not directly restrict 503A patient-specific compounding, which has always operated on a different — and narrower — legal basis (a clinician's patient-specific prescription). That said, any final regulation adds to a trend of tightening rules, and the regulatory situation for compounded semaglutide overall continues to evolve.
Can I comment on the FDA proposal?
Yes. The public comment period is open through June 29, 2026. You can submit comments via the federal rulemaking portal at regulations.gov. Comments from patients, clinicians, and healthcare advocates on access, cost, and clinical need are all relevant to the FDA's final decision.
What happens to my compounded semaglutide prescription if the rule is finalized?
A final 503B rule would affect how large-scale outsourcing facilities operate, not 503A pharmacies. If your clinic currently fills your prescription through a 503A pharmacy, that model would not be directly prohibited by the current proposal. Your clinic can tell you which model they use.
Is there a legitimate alternative to compounded semaglutide?
Yes. Brand-name Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved and available through conventional retail and specialty pharmacies. The price difference is real — often $700–$1,100 more per month without insurance — but manufacturer savings programs and some insurance plans can reduce that gap. Our cost comparison and eligibility checker can help you understand what is available.
This article reports on regulatory developments as of June 2026 and is not legal or medical advice. The regulatory situation described may change. For personal medical decisions, consult a licensed healthcare provider.
Affiliate disclosure: This site may earn a commission if you visit a clinic through a link on this page. Commission does not influence our editorial rankings or scores. See our affiliate disclosure.
